The ‘Adult Growth Hormone Deficiency (AGHD) – Epidemiology Forecast to 2030′ report from DelveInsight provides an in-depth understanding of the disease, historical and forecasted Adult Growth Hormone Deficiency (AGHD) epidemiology in the 7MM, namely the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some Key Highlights from the Adult Growth Hormone Deficiency Epidemiology Report
According to Jana Bujanova et al., the prevalence of Adult Growth Hormone Deficiency in the UK is estimated to be 1 in 10,000.
According to estimates from the Growth Hormone Foundation, over 50,000 persons in the United States are growth hormone deficient, with 6,000 new instances recorded each year, including GHD children who transition to GHD as an adult.
According to Akira Shimatsu et al. study, Adult Onset GHD affects a higher percentage of Japanese adults (80%) than Childhood Onset GHD.
To know more, request sample @ Adult Growth Hormone Deficiency Epidemiology
Adult Growth Hormone Deficiency: Overview
Adult-Onset Growth Hormone Deficiency (AGHD) is a medical condition caused by a lack of growth hormone production in the body. It promotes the production of another hormone known as insulin-like growth factor 1, which is primarily produced by the liver. These hormones work together to promote growth in children and have wide-ranging metabolic impacts in adults.
Adults with GHD are divided into two groups: Childhood Onset (GHD that began in childhood and has since progressed) and Adult Onset (GHD developed after reaching adulthood).
Adult Growth Hormone Deficiency Epidemiology Segmentation
Adult Growth Hormone Deficiency Prevalent Cases
Childhood Onset GHD, Adult Onset GHD Diagnosed Prevalent Cases
Adult Growth Hormone Deficiency Gender-Specific Prevalent Cases
Adult Growth Hormone Deficiency Diagnosed and Treatable Cases
For more insights visit, Adult Growth Hormone Deficiency Treatment Approaches
Table of Contents
1.
Key Insights
2.
Adult Growth Hormone Deficiency: Market Overview at a Glance
3.
Organisations
4.
Executive Summary
5.
Methodology
6.
Adult Growth Hormone Deficiency: Disease Background and Overview
7.
AGHD Epidemiology and Patient Population
8.
Total Prevalent Population of Adult Growth Hormone Deficiency in 7MM
9.
AGHD: United States Epidemiology
10.
AGHD: EU5 Epidemiology
11.
AGHD: Japan Epidemiology
12.
SWOT Analysis
13.
KOL Views
14.
Case studies
15.
Appendix
16.
DelveInsight Capabilities
17.
Disclaimer
18.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Related Reports
Adult Myopia Epidemiology Forecast
DelveInsight’s ‘Adult Myopia–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology Adult Myopia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/